logo-loader
viewOkyo Pharma Limited

OKYO Pharma receives US patent covering 'secret sauce' of a potential new class of pain relief drug

The protection covers a class of bovine adrenal medulla (BAM) peptides linked to certain lipids that OKYO’s scientists think may have therapeutic potential

Okyo Pharma Limited -

OKYO Pharma Limited (LON:OKYO) has been issued with a US patent for a potential new type of non-opioid analgesic being developed to treat symptoms of neuropathic pain, ocular pain, ocular inflammation and/or dry eye disease.

The protection covers a class of bovine adrenal medulla (BAM) peptides linked to certain lipids that OKYO’s scientists think may have therapeutic potential.

Chief executive, Dr Gary Jacob, said his team believe the lipid anchor component of the molecule is the “secret sauce” of the formulation.

He added that the plan was to file an investigational new drug application with the US Food & Drug Administration for a BAM candidate “as we move through 2021”.

"The publication of this patent on our BAM-lipidated analogues provides key IP protection crucial for bringing forward a candidate from this class into the clinic," Jacob told investors.

"It is important to recognize that the novel element of these drug candidates is the lipid anchor component of the molecule which we believe is the 'secret sauce' in seeing a pharmacologic benefit in the environment of the eye where tearing and other physiologic phenomena normally work against the effectiveness of drugs due to washout.”

Quick facts: Okyo Pharma Limited

Price: 7.875 GBX

LSE:OKYO
Market: LSE
Market Cap: £52.98 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Okyo Pharma Limited named herein, including the promotion by the Company of Okyo Pharma Limited in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Market Report: Airline makers and travel firms fly after Boris reveals road...

FTSE 100 rose gently as investors digested Boris Johnson’s roadmap to recovery from Covid-19. London’s blue-chip index rose by 11 to 6,623, suggesting most of the well-leaked plan was already priced in. British Airways owner IAG, aeroengine maker Rolls-Royce and aeroengineer Melrose were the...

2 weeks ago

2 min read